Total
0
Shares
Volpara Health Technologies (ASX:VHT) - Group CEO, Dr Ralph Highnam - The Market Herald
Group CEO, Dr Ralph Highnam
Source: SoundCloud
  • Volpara Health Technologies (VHT) has appointed seasoned technology executive Katherine Singson as CEO of its U.S. subsidiary Volpara Solutions
  • She has over 30 years of experience in strategy, branding, marketing and sales, including at NeXT, Apple & Pixar and Microsoft ANZ
  • The appointment is part of the company's shift from conventional medical marketing to digital channels, a transformation accelerated by COVID-19 conditions
  • Additionally, Chief Commercial Officer Mark Koeniguer will leave the company
  • Volpara shares gained 3.1 per cent today to close at $1.34

Volpara Health Technologies (VHT) has appointed Katherine Singson as CEO of its U.S. subsidiary Volpara Solutions.

The medical technology company's cancer screening software facilitates care personalised to individual patients. It is increasingly digitalising its marketing strategy, a process which will be spearheaded by Mrs Singon in the United States.

“In these uncertain times, we aim to create a nimble, responsive and tastefully relentless approach to addressing this destructive disease. Since COVID-19, the idea of actively participating in one’s own self-care in partnership with leading-edge healthcare providers is stronger than ever, and I can’t wait to get started."

While already underway, COVID-19 conditions have accelerated the digital shift, as Group CEO Dr Ralph Highnam explained.

"We've been following a conventional medical device sales and marketing strategy - you get new leads from trade shows, you go on-site to visit the customer, you do training on-site - but that has a high customer acquisition cost and is just not feasible now for some parts of the world where COVID-19 is very active."

"Thus, we've been moving for some time towards a more digital strategy - smart marketing to generate leads, smart marketing to drive demand for our products from patients, video conferencing for remote sales, virtual installs and virtual support."

Katherine Singson is a seasoned technology executive with over 30 years of experience behind her in AI start-ups to multinationals, such as NeXT, Apple & Pixar and Microsoft ANZ, and will help lead Volpara's strategic shift.

"We've been fortunate to have found Katherine Singson, an experienced technology business executive who is an expert in all aspects of digital strategy and a breast cancer survivor," said Dr Highnam.

"She was mentored by Steve Jobs, and comes with an amazing set of connections, and a way of thinking which I think will change the way people look at and detect breast cancer."

Meanwhile, Chief Commercial Officer Mark Koeniguer will leave the company and Dr Highnam thanked him for contributions.

Volpara shares gained 3.1 per cent today to close at $1.34.


Subscribe


VHT by the numbers
More From The Market Herald
Telix Pharmaceuticals (ASX:TLX)- CEO, Dr. Christian Behrenbruch - The Market Herald

" Telix Pharmaceuticals (ASX:TLX) submits NDA for prostate cancer imaging product

Telix Pharmaceuticals (TLX) has submitted a new drug application (NDA) with the U.S.
Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

" Recce Pharmaceuticals (ASX:RCE) completes $27.95M capital raise

Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million.
Cynata Therapeutics (ASX:CYP) - Managing Director & CEO, Dr Ross Macdonald - The Market Herald

" Cynata Therapeutics (ASX:CYP) receives positive results for stem cell treatment in heart attack

Cynata Therapeutics (CYP) has received positive results for its Cymerus stem cell treatment in a preclinical heart attack model.
PharmaAust Limited (ASX:PAA) - Executive Chairman, Dr Roger Aston - The Market Herald

" PharmAust (ASX:PAA) advances testing against COVID-19

PharmAust (PAA) has advanced its monepantel drugs testing against COVID-19, in the race to find a vaccine for the virus.